Ascendia Pharmaceuticals

Ascendia pharmaceuticals offers amorsol. Features: it is a technology for the production of amorphous solid dispersions. Solid dispersions are used to increase the dissolution rate, a limiting factor for the absorption of many compounds in development today. Contact us for more information.

Ascendia pharmaceuticals offers cGMP clinical batches of injectable dosage forms. Features: a dedicated, self-contained cleanroom for conducting sterile manufacturing and fill processes is maintained. Contact us for more information.

Ascendia pharmaceuticals offers cGMP clinical batches of tablet and capsule dosage forms. Features: it require capability to granulate, blend, and roller compact to make tablet batches for immediate release and modified release applications. Contact us for more information.

Transformative technologies and the opportunities afforded by the COVID-19 pandemic have spurred investment in the life sciences outsourcing sector, according to a panel of industry experts speaking at CPHI North America on Monday.

Pharma R&D productivity has remained stagnant in the new millennium, despite record industry growth. While new technology has improved productivity in nearly every other sector, efficiency in pharmaceutical R&D is declining (or as described by MedCity News — “broken”).What obstacles are in the way of improving productivity in the pharmaceutical industry? How can we meet these challenges? At Ascendia Pharma, we’re proud to have innovative strategies in place to help our clients get their drugs from R&D to market faster.